Navigation Links
Bavarian Nordic A/S - Interim Report for the Period 1 January to 30 June 2008
Date:8/19/2008

KVISTGARD, Denmark, August 19 /PRNewswire-FirstCall/ -- Today Bavarian Nordic published the company's interim report as of 30 June 2008. The full financial statements are available on the company's website. Below is an extract of the most significant matters in the report as well as events after the balance sheet date.

In the first half of 2008 Bavarian Nordic generated revenue of DKK 23 million and recorded a loss before tax of DKK 119 million. The expectations for the financial result for the full year 2008 are maintained at revenues in the level of DKK 180 million, and a pre-tax loss in the level of DKK 225 million. The main part of the revenue comprises of a milestone payment under the RFP-3 contract, which is expected in the fourth quarter of 2008. As of 30 June 2008 the Group's net free liquidity was DKK 882 million. The Company raises its expectations for the net free liquidity at year-end 2008 from approx. DKK 500 million to approx. DKK 620 milllion. The increase comprises of DKK 80 million from released trusted funds and DKK 40 million from realised fair value of forward rate agreements.

Highlights

- Bavarian Nordic partners with the National Cancer Institute in the US

In August, Bavarian Nordic entered into a scientific partnership with the National Cancer Institute. NCI and Bavarian Nordic will jointly develop new immunotherapies for the treatment of prostate cancer. Through the collaboration, the company has obtained rights to intellectual property rights covering a prostate cancer vaccine product candidate in late phase II clinical development.

- Bavarian Nordic has signed contract with Asian country for the delivery

of IMVAMUNE(R)

Bavarian Nordic has signed a three-year contract with the government of an Asian country for the delivery of a small order of IMVAMUNE(R) for the country's biodefense programme.

- More than 1,900 subjects now vaccinated with IMVAMUNE(R)

To-date, mor
'/>"/>

SOURCE Bavarian Nordic A/S
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Bavarian Nordic Update - 2007 Annual Results, IMVAMUNE(R) Delivery Contract, Strategy Process
2. Bavarian Nordic Receives $50 Million Advance Payment from HHS for Fulfilling Contract Milestones
3. LPBP Inc. - Re-filing certification of interim filings
4. Fufeng Announces 2008 Interim Results With Strong Sign of Recovery
5. BioMS Medical announces positive interim analysis on phase III trial of dirucotide (MBP8298) for multiple sclerosis
6. Chromos obtains interim order in connection with arrangement, announces annual and special meeting of shareholders and confirms mailing of information circular
7. Quest PharmaTech Announces Interim Results from Phase I/II Clinical Trial for Photodynamic Treatment for Hair Removal
8. Angiotechs corporate partner, Cook Medical, announces positive interim results for its Zilver(R) PTX(TM) clinical study
9. Clarification on Press Release Issued Earlier Today: Targeted Genetics Confirms Positive, Interim Phase 1/2 Study Findings
10. Steve Davis Joins Infectious Disease Research Institute (IDRI) as Interim CEO
11. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Combination REOLYSIN(R) and Carboplatin/Paclitaxel Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... ... July 29, 2015 , ... Brady ... GHS Label Guide . To align chemical container labeling with OSHA’s updated ... explanations of label components, an example of an accurate label, and pictogram uses ...
(Date:7/29/2015)... YORK , July 29, 2015  Therapath ... testing, announces increased partnerships with VA and Military ... Epidermal Nerve Fiber Density (ENFD) and Sweat Gland ... small fiber neuropathy ( https://therapath.com/skin ). ... Nerve Fiber Density (ENFD) on punch skin biopsy ...
(Date:7/29/2015)... SLOUGH, England , July 29, 2015  Indivior ... Application (NDA) for naloxone nasal spray was accepted and ... Administration (FDA) for the treatment of opioid overdose. This ... contains naloxone specially formulated for optimal absorption into the ... to require minimal training so individuals may be better ...
(Date:7/29/2015)... /PRNewswire/ - RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSX.V: ... to announce that the final design specifications of ... Prototypes for industrial and regulatory testing will now ... CE mark clearance to market the injector in ... (Photo: http://photos.prnewswire.com/prnh/20150729/248373 )  The ...
Breaking Biology Technology:Brady Announces a New GHS Label Guide 2Neuropathology services for VA and Military health systems 2Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 2Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 3Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 4Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 5RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 2RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 3RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 4RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 5
... Delcath Systems, Inc. (Nasdaq: DCTH ), ... Perfusion ("PHP") System for the treatment of cancers of the ... 92) of patients have been enrolled in the Phase III ... liver. The eleven participating cancer centers in this trial ...
... India, December 11 , - SCRIP Awards Recognises ... and Biotech Industries Worldwide, - Glenmark is ... Prestigious Recognition, , ... at a glittering ceremony in London at the 2008 SCRIP Awards ...
... Board to Take Immediate Action to Protect and Maximize Shareholder Value ... Biotechnology Value Fund, L.P., the owner, together with its affiliates, of ... Inc. (Nasdaq: AVGN ) announced today that it had ... with Avigen,s recent performance and continued destruction of shareholder value. ...
Cached Biology Technology:Enrollment in Delcath's Pivotal Phase III Metastatic Melanoma Clinical Trial Reaches Halfway Point 2Enrollment in Delcath's Pivotal Phase III Metastatic Melanoma Clinical Trial Reaches Halfway Point 3SCRIP, the Leading Pharmaceutical Magazine in the World Crowns Glenmark as the "Best Pharma Company in the World - SME" and the "Best Company in Emerging Markets" at the SCRIP Awards 2008 in London 2Biotechnology Value Fund Delivers Letter to Board of Directors of Avigen, Inc. 2Biotechnology Value Fund Delivers Letter to Board of Directors of Avigen, Inc. 3Biotechnology Value Fund Delivers Letter to Board of Directors of Avigen, Inc. 4Biotechnology Value Fund Delivers Letter to Board of Directors of Avigen, Inc. 5
(Date:7/31/2015)... SHENZHEN , Kina, 31. juli 2015 ... ) bliver afholdt af BGI fra den 22. - 25. ... Konferencen fejrer sin 10-års fødselsdag i år. ... verdens mest indflydelsesrige årlige møder på ,omik,-feltet, og er ... forsamlinger. ICG-10 fokuserer på nylige gennembrud ...
(Date:7/31/2015)... , 31 de julio de 2015 BGI llevará ... www.icg-10.org ) del 22 al 25 de octubre de ... La conferencia celebra su décimo aniversario este año. ... en una de las reuniones anuales más influyentes del ... una de las conferencias científicas más dinámicas, entusiastas y ...
(Date:7/31/2015)... 31 de julho de 2015 A 10 ... ) será realizada pela BGI de 22-25 de outubro de ... A conferência está celebrando seu 10 o. ... ICG se tornou uma das reuniões mais influentes do ... científicos mais dinâmicos, entusiastas e prazerosos. ...
Breaking Biology News(10 mins):Den 10. internationale konference om Genomics (ICG-10) åbner i oktober 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 3
... tell us a lot about the way species evolve after ... exceptionally broad study conducted in part by Florida State University ... the evolutionary history of rodents calls into doubt a generally ... such as a continent, evolution leads to a dramatic increase ...
... A new study shows that immune cells outside the ... presented today at the American College of Neuropsychopharmacology (ACNP) Annual ... impact on the quality of life, health and life expectancy ... of the disorder remain something of a mystery. In ...
... between genes and the environment has been pondered at least ... mid-1800s. But until the arrival of modern genomic sequencing ... environment had on a species, genetic makeup. Now, researchers ... flies that live on opposite slopes of a unique natural ...
Cached Biology News:Study of rodent family tree puts brakes on commonly held understanding of evolution 2Study of rodent family tree puts brakes on commonly held understanding of evolution 3Peripheral immune system may regulate vulnerability to depression 2Environment drives genetics in 'Evolution Canyon'; discovery sheds light on climate change 2Environment drives genetics in 'Evolution Canyon'; discovery sheds light on climate change 3
Oxidative Stress-Inducible Protein Tyrosine Phosphatase...
... Anti-MAGE-D2/NRAGE-Like 2b GenBank ... Immunogen : peptide (C-QSQENQDTRPKVKAKK), corresponding ... human MAGE-D2/NRAGE-Like 2b Formulation: antiserum ... 30% glycerol Quality Assurance: routinely ...
Antibody specific for histone H3 acetylated at any of the five N-terminal lysine residues. Rabbit polyclonal serum. Antigen: Synthetic peptide derived from histone H3 N-terminal region, mulitpliy...
The FailSafe™ PROBES Real-Time PCR System enables rapid, precise optimization of PCR experiments in which the product is detected using fluorescent target-specific labeled probes....
Biology Products: